Can Fite Biopharma Ltd ADR (CANF)
Can-Fite Biopharma Ltd. ADR is a depositary receipt listed on the NYSE that represents common stock of Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company based in Ramat Gan, Israel. The issuer focuses on orally available small-molecule therapies for oncology, liver inflammatory diseases, and erectile dysfunction. Its lead candidate, Piclidenoson, has completed a Phase III trial in psoriasis. Namodenoson is in Phase III development for liver cancer, Phase IIa testing for pancreatic cancer, and Phase IIb evaluation for metabolic associated steatohepatitis. The company is also advancing CF602 in pre-clinical studies for erectile dysfunction and is developing a commercial blood test kit for A3AR biomarkers. Can-Fite BioPharma was founded in 1994 and adopted its current name in 2001.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-CANF
|
$3.58
|
9.8% Upside
|
Fair
|
$8
|
145.4% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 26, 2026
|
-0.7x
|
1.3x
|
17.6x
|
7.323 M
|
-1.726 M
|
1.0%
|
100.0%
|
-58.0
|
—
|
91.1%
|
